Saturday 08/19/2017

mybesthealthportal.net : The leading source for health, fitness, weight loss, nutrition and anti aging health and wellness information


CONNECT :

Top Health Headlines

Depression strikes older women more ofte…

Depression strikes older women more often than men

Older women are more prone to depression and are more likely to remain depressed than are older men,... Read more

FDA Won't Approve New Weight Loss Drug Contrave

Rate this item
(0 votes)

The FDA issued a response letter that asks Orexigen Therapeutics, the maker of Contrave, to check for heart attack or other cardiovascular risks by conducting a "randomized, double-blind, placebo-controlled trial." Randomized, double-blind, placebo-controlled trial randomly assign patients to receive either a drug or a placebo (dummy pill).

In order for Contrave to receive FDA approval, the study must demonstrate that Contrave's heart risks do not exceed the Contrave's benefits. The trial could take years, according to experts.

"We are surprised and extremely disappointed with the Agency's request in light of the extensive discussion and resulting vote on this topic at the December 7 Advisory Committee meeting," President and CEO of Orexigen Michael Narachi says in a news release. At that meeting, an FDA advisory committee voted 13 to 7 to recommend approval of Contrave despite its modest effectiveness in helping people lose weight.

About Contrave

Contrave (naltrexone SR/bupropion SR) is an investigational medication for the treatment of obesity.

Contrave combines two well-established drugs, naltrexone and bupropion, in a sustained release formulation (SR) into one that experts hope will control eating and help people lose weight safely.

The two drugs are naltrexone, used to treat alcohol and cocaine addiction, and bupropion (known mainly as Wellbutrin), an antidepressant, which also helps people quit smoking.

Together, the drugs affect both appetite or satiety and motivation, or the drive to eat.

Naltrexone impacts the brain's opioid receptors, which are involved in feelings of pleasure and reward. Bupropion increases brain levels of dopamine, the notorious "feel good" chemical that is also released when cocaine or amphetamines are taken.

"It gives you a little kick so you feel okay and don't have to look for food," says Gene-Jack Wang, MD, a senior scientist with Brookhaven National Laboratory in Upton, New York. " Contrave is very similar to amphetamines, but it's not so effective, [which is] better because if it's too effective, it makes you more addicted."

Contrave’s Risks May Outweigh Its Benefits

In previous studies, people taking Contrave lost only 4.2% more of their body weight compared to those taking a placebo. This is below the FDA standard of 5%. It may be Contrave’s “kick” that may be the cause of FDA’s concern.

Series of FDA Rejections of Weight Loss Drugs

Contrave is the third weight loss drug in recent months to be rejected. The FDA formally rejected locaserin from Arena Pharmaceuticals and Qnexa from Vivus in October 2010.

The agency has become very focused on the safety of diet drugs because of their potential widespread use by not only obese patients but by people looking to lose a small amount of weight. Nearly two-thirds of American adults are overweight or obese.

Contrave is an experimental drug that combines naltrexone, an opioid blocker used to treat addictions, and bupropion, an antidepressant, to suppress food cravings for the treatment of obesity, according to its maker.

SOURCES:

News release, Orexigen Therapeutics Inc.

FDA News Release

Last modified on Monday, 12 December 2011 06:28
Login to post comments

Sponsors

Advertisers

RSS

Most Viewed Articles

Most Recent Comments

Stock Market

Loading
Chart
o Dow Jones 21,674.51 ▼76.22 (-0.35%)
o S&P 500 2,425.55 ▼4.46 (-0.18%)
o NASDAQ 6,216.53 ▼5.39 (-0.09%)
INDEXDJX:.DJI

Dow Jones

Company ID [INDEXDJX:.DJI] Last trade:21,674.51 Trade time:4:37PM EDT Value change:▼76.22 (-0.35%)
INDEXSP:.INX

S&P 500

Company ID [INDEXSP:.INX] Last trade:2,425.55 Trade time:4:37PM EDT Value change:▼4.46 (-0.18%)
INDEXNASDAQ:.IXIC

NASDAQ

Company ID [INDEXNASDAQ:.IXIC] Last trade:6,216.53 Trade time:5:15PM EDT Value change:▼5.39 (-0.09%)

Facebook Fans

Tools

Nutrition Tools

nutrition tools
Our nutrition tools include free food management systems, meal calculators and a search tool that provides nutrient and calorie content of 7,146 different foods.

Weight Loss Tools

weight-loss-tools
Our weight loss tools and calculators can give you the edge you need to can help you reach your weight loss goals and maintain your weight . They are free to and easy to use.

Metabolic Tools

bmi_tool
Use our free metabolic tools and calculators to determine your ideal body weight, your target heart rate, BMI, BMR and more.

Health Tools

doctors_health_tools
Our health tools and health calculators can help you reach your goals and control your health, nutrition and more. It's easy and free to get started.
External links are provided for reference purposes. The World News II is not responsible for the content of external Internet sites. Template Design © Joomla Templates | GavickPro. All rights reserved.

Use of this web site constitutes acceptance of the MyBestHealthPortal.com Terms of Service and Privacy Policy. The information on this site is for educational use only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Placement of product information or advertisements does not constitute and endorsement of the products of services described. MyBestHealthPortal.com is a registered trademark of the Behar Health Network.

Login or Register

Facebook user?

You can use your Facebook account to sign into our site.

Log in with Facebook

LOG IN

Register

User Registration
or Cancel